REYON Pharmaceutical Co., Ltd.
KRX:102460.KS
13350 (KRW) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 151,071.144 | 154,038.839 | 142,801.368 | 130,034.153 | 131,557.875 | 122,990.417 | 126,253.126 | 121,847.22 | 114,507.235 | 112,112.067 | 109,693.36 | 114,334.848 | 124,350.931 | 120,827.191 | 95,187.341 | 72,932.904 | 55,906.318 |
| Cost of Revenue
| 74,252.727 | 72,310.911 | 63,363.648 | 57,449.436 | 57,296.353 | 54,467.058 | 53,601.502 | 51,528.771 | 47,522.492 | 48,695.393 | 46,198.177 | 47,016.782 | 45,140.908 | 43,150.4 | 38,122.101 | 30,234.562 | 22,738.361 |
| Gross Profit
| 76,818.417 | 81,727.929 | 79,437.72 | 72,584.718 | 74,261.523 | 68,523.36 | 72,651.623 | 70,318.449 | 66,984.743 | 63,416.674 | 63,495.183 | 67,318.066 | 79,210.023 | 77,676.791 | 57,065.24 | 42,698.342 | 33,167.957 |
| Gross Profit Ratio
| 0.508 | 0.531 | 0.556 | 0.558 | 0.564 | 0.557 | 0.575 | 0.577 | 0.585 | 0.566 | 0.579 | 0.589 | 0.637 | 0.643 | 0.6 | 0.585 | 0.593 |
| Reseach & Development Expenses
| 8,646.955 | 6,705.318 | 9,725.328 | 6,583.817 | 3,724.266 | 6,697.283 | 3,454.221 | 6,494.65 | 2,183.28 | 3,343.102 | 2,499.52 | 2,719.053 | 3,062.598 | 1,373.127 | 1,546.577 | 1,414.877 | 1,199.396 |
| General & Administrative Expenses
| 13,571.385 | 13,176.154 | 12,347.626 | 11,082.934 | 10,498.202 | 9,538.757 | 11,869.276 | 13,731.987 | 12,027.475 | 9,061.577 | 9,708.905 | 10,987.409 | 11,176.606 | 11,621.875 | 6,363.477 | 5,702.128 | 4,435.719 |
| Selling & Marketing Expenses
| 17,960.297 | 23,671.913 | 23,185.118 | 22,017.181 | 24,196.936 | 22,093.62 | 21,009.78 | 18,832.777 | 15,323.135 | 15,338.117 | 15,574.545 | 14,456.212 | 15,674.186 | 15,562.346 | 12,412.201 | 7,138.751 | 5,679.422 |
| SG&A
| 65,421.406 | 36,848.067 | 35,532.744 | 33,100.115 | 34,695.138 | 31,632.377 | 32,879.056 | 32,564.764 | 27,350.61 | 24,399.694 | 25,283.45 | 25,443.621 | 26,850.792 | 27,184.221 | 18,775.678 | 12,840.879 | 10,115.141 |
| Other Expenses
| -981.054 | 28,851.852 | 31,133.583 | 29,449.058 | 27,944.026 | 68.078 | -411.731 | -1,069.257 | -189.731 | -1,344.163 | -109.119 | -22.474 | -72.719 | -794.147 | -397.249 | -494.9 | -913.378 |
| Operating Expenses
| 75,049.415 | 72,405.237 | 76,391.655 | 69,132.99 | 66,363.43 | 66,063.579 | 56,650.462 | 56,253.441 | 47,147.862 | 46,693.51 | 46,063.86 | 46,093.199 | 54,843.732 | 50,675.027 | 36,391.229 | 29,483.741 | 23,379.538 |
| Operating Income
| 1,769.002 | 7,407.427 | 5,733.918 | 4,149.719 | 7,898.093 | 2,459.781 | 16,001.162 | 14,065.007 | 19,836.881 | 16,723.163 | 17,431.323 | 21,224.867 | 24,366.291 | 27,001.767 | 20,674.012 | 13,214.601 | 9,788.419 |
| Operating Income Ratio
| 0.012 | 0.048 | 0.04 | 0.032 | 0.06 | 0.02 | 0.127 | 0.115 | 0.173 | 0.149 | 0.159 | 0.186 | 0.196 | 0.223 | 0.217 | 0.181 | 0.175 |
| Total Other Income Expenses Net
| 3,223.144 | -513.511 | 110.844 | 217.97 | -64.678 | -1,611.267 | 354.647 | -330.082 | 777.183 | -1,630.967 | 837.869 | 1,431.464 | 441.187 | -203.041 | 299.415 | -1,623.21 | -1,335.704 |
| Income Before Tax
| 4,992.146 | 6,893.916 | 5,844.762 | 4,367.689 | 7,833.415 | 848.513 | 16,355.808 | 13,734.926 | 20,614.064 | 15,092.197 | 18,269.192 | 22,656.331 | 24,807.479 | 26,798.723 | 20,973.426 | 11,591.391 | 8,452.715 |
| Income Before Tax Ratio
| 0.033 | 0.045 | 0.041 | 0.034 | 0.06 | 0.007 | 0.13 | 0.113 | 0.18 | 0.135 | 0.167 | 0.198 | 0.199 | 0.222 | 0.22 | 0.159 | 0.151 |
| Income Tax Expense
| 448.59 | -539.767 | 307.51 | 523.262 | 1,893.613 | -492.979 | 3,468.908 | 3,033.557 | 9,276.131 | 3,498.911 | 6,976.23 | 5,665.772 | 5,028.104 | 6,816.789 | 4,685.433 | 3,525.844 | 2,366.294 |
| Net Income
| 3,583.373 | 7,433.682 | 5,537.252 | 3,844.427 | 5,941.67 | 1,342.893 | 12,886.901 | 10,701.369 | 11,337.933 | 11,593.286 | 11,292.961 | 16,990.559 | 19,779.374 | 19,981.933 | 16,287.993 | 8,065.547 | 6,086.421 |
| Net Income Ratio
| 0.024 | 0.048 | 0.039 | 0.03 | 0.045 | 0.011 | 0.102 | 0.088 | 0.099 | 0.103 | 0.103 | 0.149 | 0.159 | 0.165 | 0.171 | 0.111 | 0.109 |
| EPS
| 195.38 | 414.51 | 305.44 | 225.75 | 287.64 | 79.41 | 752.94 | 481.15 | 662.9 | 677.98 | 659.88 | 993.21 | 1,156.11 | 1,194.57 | 1,003.77 | 554.3 | 11,677 |
| EPS Diluted
| 195.38 | 414.51 | 305.44 | 225.75 | 287.64 | 79.41 | 741.18 | 481.15 | 662.9 | 677.98 | 659.88 | 993.21 | 1,156.11 | 1,194.57 | 1,003.77 | 505.28 | 11,677 |
| EBITDA
| 6,551.236 | 11,940.937 | 10,399.621 | 9,202.957 | 12,531.206 | 6,401.458 | 18,646.829 | 16,007.121 | 21,590.288 | 18,319.595 | 20,696.729 | 25,107.537 | 27,188.563 | 29,334.303 | 23,970.018 | 14,632.309 | 12,294.059 |
| EBITDA Ratio
| 0.043 | 0.078 | 0.073 | 0.071 | 0.095 | 0.052 | 0.148 | 0.131 | 0.189 | 0.163 | 0.189 | 0.22 | 0.219 | 0.243 | 0.252 | 0.201 | 0.22 |